抗血管内皮生长因子药种类及其眼科应用

摘要
图/表
参考文献
相关文章 (8)

[1]	Schwesinger C, Yee C, Rohan R M, et al. Intrachoroidal neovascularization in transgenic mice over expressing vascularendothelial growth factor in the retinal pigment epithelium[J]. Am J Pathol, 2001, 158(3): 1161-1172.
[2]	Bhisitkul R B. Vascular endothelial growth factor biology: clinical implications for ocular treatments [J]. Br J Ophthalmol, 2006, 90(12):1542-1547.
[3]	Dor Y, Porat R, Keshet E. Vacular endothelial growth factor and vascular adjustments to perturbations in oxygen homeostasis[J]. Am J Physiol Cell Physiol, 2001, 280(6): 1367-1374.
[4]	Fine S L,Martin D F,Kirkpatrick P.Pegaptanib sodium[J].Nat Rev Drug Discov,2005,4: 187-188.
[5]	于问利,毕宏生. Avastin在眼科应用的研究进展[J]. 国际眼科杂志,2008,8(4):810-812.
[6]	Nepomuceno A B,Takaki E,Paes de Almeida F P,et al. A prospective randomized trial of intravitreal bevacizumab versus ranibizumab for the management of diabetic macular edema[J]. Am J Ophthalmol,2013,156( 3) : 502-510.
[7]	Rosenfeld P J, Rich R M, Lalwani G A. Ranibizumab: phase Ⅲ clinical trial results[J]. Ophthamlol Clin North Am,2006,19(3):361-372.
[8]	Chen Y,Wiesmann C,Fuh G,et al. Selection and analysis of anoptimized anti-VEGF antibody: crystal structure of an affinity matured Fab in complex with antigen[J]. J Mol Biol,1999,293: 865-881.
[9]	杜宇翔,郭大东,司俊康,等.贝伐单抗和雷珠单抗治疗渗出型老年性黄斑变性有效性Meta 分析[J].中华眼底病杂志,2014,30(3):304-307.
[10]	Curtis L H,Hammill B G,Schulman K A,et al.Risks of mortality,myocardial infarction,bleeding,and stroke associated with therapies for age-related macular degeneration[J].Graefes Arch Clin Exp Ophthalmol,2011,249:161-162.
[11]	刘姝林,陈有信.抗VEGF 药物治疗视网膜中央静脉阻塞并发黄斑水肿的Meta 分析[J].中华实验眼科杂志,2014,32(1) :56-61.
[12]	Parmeggiani F,Sorrentino F S,Romano M R,et al. Mechanism of inflammation in age-related macular degeneration: an up-to-date ongenetic landmarks[J].Mediators Inflamm,2013,2013: 435607.
[13]	Bhutto I A, Mcleod D S, HasegswaT, et al. Pigment epithelium derived factor (PEDF) and vascufar endothelial growth factor(VEGF)in agedhuman choroid and eyes with age-related macular degeneration[J]. Exp Eye Res, 2006, 82: 99-110.
[14]	Braithwaite T,Nanji A A,Lindsley K,et al. Anti-vascular endothelial growth factor for macular oedema secondary to central retinal veinocclusion[J/CD]. Cochrane Database Syst Rev,2014,5: CD007325.
[15]	Christian R C,Dumesic D A,Behrenbeck T,et al. Prevalence andpredictors of coronary artery calcification in women with polycysticovary syndrome[J]. J Clin Endocrinol Metab,2003,88(6):2562-2568.
[16]	Hall L B,Zebardast N,Huang J J,et al.Aflibercept in the treatmentof neovascular age-related macular degeneration in previously treatedpatients[J].J Ocul Pharmacol Ther,2014,30(4):346-352.
[17]	雷春燕.眼科新一代抗血管内皮生长因子药物的基础研究及临床试验进展[J].中华实验眼科杂志,2014,32(10):938-942.
[18]	Schmidt-Erfurth U,Kaiser P K,Korobelnik J F,et al.Intravitrealaflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies[J]. Ophthalmology,2014,121(1):193-201.
[19]	Bandello F,Cunha-Vaz J,Chong N V,et al. New approaches for the treatment of diabetic macular oedema: recommendations by an expert panel[J]. Eye (Lond),2012,26(4): 485-493.
[20]	Zechmeister-Koss I,Huic M. Vascular endothelial growth factor inhibitors (anti-VEGF) in the management of diabetic macular oedema: a systematic review[J]. Br J Ophthalmol,2012,96(2):167-178.
[21]	Parravano M,Menchini F,Virgili G. Antiangiogenic therapy withanti-vascular endothelial growth factor modalities for diabetic macular oedema [J/CD]. Cochrane Database SystRev,2009 (4): CD007419.
[22]	Li J,Cui Y,Wang Q,et al. The proliferation of malignant melanomacells could be inhibited by ranibizumab via antagonizing VEGF through VEGFR1[J]. Mol Vis,2014,20: 649-660.
[23]	Diabetic Retinopathy Clinical Research Network,Elman M J,Qin H,et al. Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results[J]. Ophthalmology,2012,119(11): 2312-2318.
[24]	Lang G E,Berta A,Eldem B M,et al. Two-year safety and efficacy of ranibizumab 0.5 mg in diabetic macular edema: interim analysisof the RESTORE extension study[J]. Ophthalmology,2013,120(10): 2004-2012.
[25]	Thomas B J,Shienbaum G,Boyer D S,et al. Evolving strategies in the management of diabetic macular edema:clinical trials and current management[J]. Can J Ophthalmol,2013,48(1): 22-30.
[26]	Sultan M B,Zhou D,Loftus J,et al. A phase 2/3,multicenter,randomized,double-masked,2-year trial of pegaptanib sodium for the treatment of diabetic macular edema[J].Ophthalmology,2011,118(6): 1107-1118.
[27]	Mirshahi A,Roohipoor R,Lashay A,et al. Bevacizumab-augmentedretinal laser photocoagulation in proliferative diabetic retinopathy: a randomized double-masked clinical trial[J].Eur J Ophthalmol,2008,18(2): 263-269.
[28]	Krzystolik M G,Filippopoulos T,Ducharme J F,et al. Pegaptanibasan adjunctive treatment for complicated neovascular diabetic retinopathy[J]. Arch Ophthalmol,2006,124(6): 920-921.
[29]	Yeh P T,Yang C M,Lin Y C,et al. Bevacizumab pretreatment in vitrectomy with silicone oil for severe diabetic retinopathy[J].Retina,2009,29(6): 768-774.
[30]	Ahmadieh H,Shoeibi N,Entezari M,et al.Intravitrealbevacizumab for prevention of early postvitrectomy hemorrhage in diabeticpatients:a randomized clinical trial[J]. J Ophthalmology,2009,116(10): 1943-1948.
[31]	Stewart M W. Aflibercept(VEGF Trap-eye): the newest anti-VEGF drug[J]. Br J Ophthalmol,2012,96: 1157-1158.
[32]	Rizzo S,Genovesi-Ebert F,Di Bartolo E,et al. Injection of intravitreal bevacizumab ( Avastin) as a preoperative adjunct before vitrectomy surgery in the treatment of severe proliferative diabetic retinopathy (PDR)[J]. Graefes Arch Clin Exp Ophthalmol,2008,246: 837-842.
[33]	张军燕,马凯. 抗血管内皮生长因子药物辅助治疗眼内新生血管性疾病的现状与展望[J/CD]. 中华眼科医学杂志:电子版,2013 (2): 67-73.
[34]	Soohoo JR,Seibold L K,Kahook M Y. Recent advances in the management of neovascular glaucoma[J]. Semin Ophthalmol 2013, 28(3):165-172.
[35]	李娇,袁援生,钟华,等. 新生血管性青光眼的治疗进展[J].国际眼科杂志,2014(6): 1037-1040.
[36]	Holz F G,Roider J,Ogura Y,et al. VEGF Trap-Eye for macularoedema secondary to central retinal vein occlusion: 6-monthresults of the phase Ⅲ GALILEO study[J]. Br J Ophthalmol,2013,97: 278-284.
[37]	Autrata R,Senková K,Holousová M,et al. Effects of intravitrealpegaptanib or bevacizumab and laser in treatment ofthreshold retinopathy of prematurity in zone I and posteriorzone Ⅱ--four years results[J].Cesk Slov Oftalmol, 2012,68(1):29-36.
[38]	Mintz-Hittner H A,Kennedy K A,Chuang A Z, et al. Efficacy of intravitrealbevacizumab forstage 3﹢retinopathy of prematurity[J]. N Engl J Med,2011,364(7): 603-615.
[39]	Bertelsen M, Linneberg A, Christoffersen N, et al. Mortality in patientswith central retinal vein occlusion [J]. Ophthalmology, 2014, 121(3): 637-642.
[40]	Higashiyama T, Sawada O, Kakinoki M, et al. Prospective comparisons of intravitreal injections of triamcinolone acetonide and bevacizumab for macular oedema due to branch retinal vein occlusion[J]. Acta Ophthalmol, 2013, 91(4): 318-324.
[41]	Brown D M,Campochiaro P A,Singh R P,et al. Ranibizumab formacular edema following central retinal vein occlusion: six-monthprimary end point results of a phase Ⅲ study[J]. Ophthalmology,2010,117:1124-1133.
[42]	Lozano D C, Twa M D. Development of a rat schematic eye from invivo biometry and the correction of lateral magnification in SD-OCT imaging [J]. Invest Ophthalmol Vis Sci, 2013, 54(9): 6446-6455.